Editorial comment on: Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma.

摘要

During the past few years, several studies have been performed on renal cell carcinoma (RCC) to identify the prognostic factors predictive of poor cancer-related outcome [1]. Specifically, those patients harboring RCC with lymph node metastases [2], adrenal gland invasion, vena cava thrombosis above the diaphragm, or concomitant perirenal fat and vena cava thrombosis below the diaphragm [3] are those with higher probabilities of experiencing cancer-related death. Despite significant efforts to identify the patients with the poorest prognoses, no adjuvant treatment is currently available to improve the prognosis of patients after surgery [4].